The American healthcare system presents a deeply troubling paradox where having health insurance offers no guarantee of financial security, a reality starkly illustrated by the story of Sarah Monroe. A 43-year-old from the Cleveland area, Monroe and her family enjoyed a comfortable, middle-class
Allow me to introduce Ivan Kairatov, a distinguished biopharma expert whose innovative research and development work has significantly advanced our understanding of cellular signaling and protein interactions. With a profound focus on transporter regulation, Ivan has been at the forefront of
Imagine a world where a single shot at birth could shield a child from a devastating liver disease, yet the decision to administer it hangs in a delicate balance of science, public opinion, and political will. In the United States, the hepatitis B vaccine, a cornerstone of infant health for over
Imagine a world where a persistent, hacking cough in a child could be diagnosed as whooping cough in under 20 minutes, right at the doctor’s office, preventing weeks of uncertainty and potential spread. This scenario is now closer to reality with Roche’s latest FDA-cleared point-of-care test for
Imagine a world where a diagnosis of gastric cancer no longer carries the weight of a dire prognosis, where innovative treatments offer a real chance at long-term survival even for those in the early stages of this aggressive disease. This vision is inching closer to reality with the recent
For thousands living with spinal muscular atrophy who aged out of early approvals, the FDA’s greenlight of an intrathecal gene therapy redrew the treatment map and challenged long‑held limits. The authorization of Itvisma, an intrathecal formulation of onasemnogene abeparvovec for patients two
